Abstract
People with previous SARS-CoV-2 infection mount potent immune responses to COVID-19 vaccination, but long-term effects of prior infection on these immune responses are unknown. We investigated the long-term impact of prior SARS-CoV-2 infection on humoral and cellular immune responses in healthcare workers receiving the mRNA BNT162b2 or the adenovirus vectored ChAdOx1 nCoV-19 vaccine. Vaccination with both vaccine platforms resulted in substantially enhanced T cell immune responses, antibody responses to spike and neutralizing antibodies effective against ten SARS-CoV-2 variants following SARS-CoV-2 infection, compared to in naïve individuals. The enhanced immune responses sustained over seven months following vaccination. These findings imply that prior infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programs.
One-Sentence Summary SARS-CoV-2 infection prior to vaccination leads to substantial and durable increases in immune memory responses.
Competing Interest Statement
SoH has participated on AstraZeneca COVID-19 SCG Virtual Advisory Board. Otherwise, the authors declare no competing interests.
Funding Statement
Jonas & Christina af Jochnick foundation (CT) Lundblad family foundation (CT) Region Stockholm (CT) Knut and Alice Wallenberg foundation (CT, SM) Jonas Soderquists scholarship (CT) Science for Life Laboratory (PN) Erling-Persson family foundation (SoH) Center for Innovative Medicine (JK) Swedish Research Council (JK)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by the Swedish Ethical Review Authority (dnr 2020-01653) and written informed consent was obtained from all study participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
T cell data has now been analyzed and added to the paper
Data Availability
The anonymized datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
